S
Sai-Hong Ignatius Ou
Researcher at University of California, Irvine
Publications - 385
Citations - 34075
Sai-Hong Ignatius Ou is an academic researcher from University of California, Irvine. The author has contributed to research in topics: Crizotinib & Lung cancer. The author has an hindex of 75, co-authored 308 publications receiving 27148 citations. Previous affiliations of Sai-Hong Ignatius Ou include University of Texas Southwestern Medical Center & University of Lyon.
Papers
More filters
Journal ArticleDOI
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak,Yung-Jue Bang,D. Ross Camidge,Alice T. Shaw,Benjamin Solomon,Robert G. Maki,Sai-Hong Ignatius Ou,Bruce J. Dezube,Pasi A. Jänne,Daniel B. Costa,Marileila Varella-Garcia,Woo-Ho Kim,Thomas J. Lynch,Panos Fidias,Hannah Stubbs,Jeffrey A. Engelman,Lecia V. Sequist,Weiwei Tan,Leena Gandhi,Mari Mino-Kenudson,Greg C. Wei,S. Martin Shreeve,Mark J. Ratain,Jeffrey Settleman,James G. Christensen,Daniel A. Haber,Keith D. Wilner,Ravi Salgia,Geoffrey I. Shapiro,Jeffrey W. Clark,A. John Iafrate +30 more
TL;DR: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients, and the drug resulted in grade 1 or 2 gastrointestinal side effects.
Journal ArticleDOI
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Solange Peters,D. Ross Camidge,Alice T. Shaw,Shirish M. Gadgeel,Jin S. Ahn,Dong Wan Kim,Sai-Hong Ignatius Ou,Maurice Perol,Rafal Dziadziuszko,Rafael Rosell,Ali Zeaiter,Emmanuel Mitry,Sophie Golding,Bogdana Balas,Johannes Noe,Peter N. Morcos,Tony Mok +16 more
TL;DR: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK‐positive NSCLC and independent review committee–assessed progression‐free survival were consistent with those for the primary end point.
Journal ArticleDOI
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw,Sai-Hong Ignatius Ou,Yung-Jue Bang,D. Ross Camidge,Benjamin Solomon,Ravi Salgia,Gregory J. Riely,Marileila Varella-Garcia,Geoffrey I. Shapiro,Daniel B. Costa,Robert C. Doebele,Long P. Le,Zongli Zheng,Zongli Zheng,Weiwei Tan,Patricia Stephenson,S. Martin Shreeve,L. Tye,James G. Christensen,Keith D. Wilner,Jeffrey W. Clark,A. John Iafrate +21 more
TL;DR: Crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC, and ROS1 rearrangement defines a second molecular subgroup of NSCLCs for which crizotin ib is highly active.
Journal ArticleDOI
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon,Alice T. Shaw,Sai-Hong Ignatius Ou,Ryohei Katayama,Christine M. Lovly,Nerina T. McDonald,Pierre P. Massion,Christina Siwak-Tapp,Adriana Gonzalez,Rong Fang,Eugene J. Mark,Julie M. Batten,Haiquan Chen,Keith D. Wilner,Eunice L. Kwak,Jeffrey W. Clark,David P. Carbone,Hongbin Ji,Jeffrey A. Engelman,Mari Mino-Kenudson,William Pao,A. John Iafrate +21 more
TL;DR: ROS1 rearrangement defines a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK-rearranged NSCLCs, and crizotinib shows in vitro activity and early evidence of clinical activity in ROS1- rearrangedNSCLC.
Journal ArticleDOI
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D. Ross Camidge,Yung-Jue Bang,Eunice L. Kwak,A. John Iafrate,Marileila Varella-Garcia,Stephen B. Fox,Gregory J. Riely,Benjamin Solomon,Sai-Hong Ignatius Ou,Dong Wan Kim,Ravi Salgia,Panagiotis Fidias,Jeffrey A. Engelman,Leena Gandhi,Pasi A. Jänne,Daniel B. Costa,Geoffrey I. Shapiro,Patricia LoRusso,Katherine Ruffner,Patricia Stephenson,Yiyun Tang,Keith D. Wilner,Jeffrey W. Clark,Alice T. Shaw +23 more
TL;DR: Crizotinib is well tolerated with rapid, durable responses in patients with ALK-positive NSCLC and there seems to be potential for ongoing benefit after initial disease progression in this population, but a more formal definition of ongoing benefit in this context is needed.